Evidence map›Paper›PMID 29694241›Full record

Trial reportJournal of child and adolescent psychopharmacology2018

A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism.

L Eugene Arnold, Nicole Ober, Michael G Aman, Benjamin Handen, Tristram Smith, Xueliang Pan, Susan L Hyman, Jill Hollway, Luc Lecavalier, Kristin Page and 1 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of child and adolescent psychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00844753 (Atomoxetine, Placebo and Parent Management Training in Autism), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00844753 phase4completednot on this map

Atomoxetine, Placebo and Parent Management Training in Autism

TypeinterventionalSponsorUniversity of RochesterRan2008 to 2014Enrolled128ConditionsAutism, Pervasive Development Disorder, Asperger's Disorder, Attention Deficit Hyperactivity DisorderArmsatomoxetine, Placebo, Parent Management Training
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

L Eugene Arnold1 Nisonger Center UCEDD, The Ohio State University , Columbus, Ohio.
Nicole Ober2 Department of Psychiatry, School of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania.
Michael G Aman1 Nisonger Center UCEDD, The Ohio State University , Columbus, Ohio.
Benjamin Handen2 Department of Psychiatry, School of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania.
Tristram Smith3 Department of Pediatrics, Division of Developmental and Behavioral Pediatrics, University of Rochester , Rochester, New York.
Xueliang Pan4 Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University , Columbus, Ohio.
Susan L Hyman3 Department of Pediatrics, Division of Developmental and Behavioral Pediatrics, University of Rochester , Rochester, New York.
Jill Hollway1 Nisonger Center UCEDD, The Ohio State University , Columbus, Ohio.
Luc Lecavalier1 Nisonger Center UCEDD, The Ohio State University , Columbus, Ohio.
Kristin Page1 Nisonger Center UCEDD, The Ohio State University , Columbus, Ohio.
Robert Rice1 Nisonger Center UCEDD, The Ohio State University , Columbus, Ohio.
University of Pittsburgh · USThe Ohio State University · US

Funding

UNIVERSITY OF ROCHESTER'S RESEARCH ASSOCIATE ORGANIZATIONUL1RR024160 · NCRR · UNIVERSITY OF ROCHESTER · PI PEARSON, THOMAS ARTHUR · 2006 to 2011
$38.7M
The Ohio State University Center for clinical and Translational ScienceUL1TR001070 · NCATS · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2013 to 2017
$22.6M
2/3-Atomoxetine Placebo and Parent Training in AutismR01MH079080 · NIMH · OHIO STATE UNIVERSITY · PI AMAN, MICHAEL GEORGE · 2008 to 2012
$1.8M
3/3-Atomoxetine Placebo and Parent Training in AutismR01MH083247 · NIMH · UNIVERSITY OF ROCHESTER · PI SMITH, TRISTRAM H · 2008 to 2012
$1.4M
1/3-Atomoxetine Placebo and Parent Training in AutismR01MH079082 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HANDEN, BENJAMIN L · 2008 to 2012
$1.4M
NCATS NIH HHS UL1 TR001070NCRR NIH HHS UL1 RR024160NIMH NIH HHS R01 MH079080NIMH NIH HHS R01 MH079082NIMH NIH HHS R01 MH083247
6 · The paper itself

Abstract

objectiveTo examine status of children with autism spectrum disorder (ASD) 10 months after a 34-week clinical trial of atomoxetine (ATX) and parent training (PT).

methodsIn a 2 × 2 design, 128 children with ASD and attention-deficit/hyperactivity disorder (ADHD) were randomly assigned ATX, PT+placebo, PT+ATX, or placebo alone. PT was weekly for 10 weeks, and then monthly. ATX/placebo was titrated over 6 weeks [≤1.8 mg/kg/d], and then maintained until week 10. Responders continued to week 34 or nonresponse. Placebo nonresponders had a 10-week ATX open trial; ATX nonresponders were treated clinically. All continued to week 34. With no further treatment from the study, all were invited to follow-up (FU) at 1.5 years postbaseline; 94 (73%) participated. Changes from Week 34 to FU and from baseline to FU were tested by one-way analysis of variance or chi-squared test. PT versus no PT was tested by chi-squared test, Fisher's exact test, Welch's t-test, Student's t-test, and Mann-Whitney's U test.

resultsFor the whole sample, the primary outcomes (parent-rated ADHD on the Swanson, Nolan, and Pelham [SNAP] scale and noncompliance on the Home Situations Questionnaire [HSQ]) deteriorated mildly from week 34 to FU, but were still substantially better than baseline (SNAP: t = 12.177, df = 93, p < 0.001; HSQ: t = 8.999, df = 93, p < 0.001). On the SNAP, 61% improved ≥30% from baseline (67% did at week 34); on noncompliance, 56% improved ≥30% from baseline (77% did at week 34). Outcomes with PT were not significantly better than without PT (SNAP p = 0.30; HSQ p = 0.27). Originally assigned treatment groups did not differ significantly. Only 34% still took ATX; 27% were taking stimulants; and 25% took no medication.

conclusionsThe majority retained their 34-week end-of-study improvement 10 months later, even though most participants stopped ATX. For some children, ATX continuation may not be necessary for continued benefit or other drugs may be necessary. Cautious individual clinical experimentation may be justified. Twelve sessions of PT made little long-term difference. ClinicalTrials.gov Identifier: Atomoxetine, Placebo and Parent Management Training in Autism (Strattera) (NCT00844753).

Indexed as

AdolescentAdrenergic Uptake InhibitorsAtomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityAutism Spectrum DisorderChildDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleParentsProblem BehaviorPsychiatric Status Rating ScalesSurveys and QuestionnairesTreatment OutcomeAdrenergic Uptake InhibitorsAtomoxetine HydrochlorideADHDatomoxetineautism spectrum disorderfollow-up studiesparent training

Identifiers

PMID29694241
PMCPMC5994674
OpenAlexW2801151975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.